- Home
- MP vs KYMR Comparison
MP vs KYMR Comparison
Compare MP & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MP | KYMR |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.6B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MP | KYMR |
|---|---|---|
| Price | $50.64 | $115.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 26 |
| Target Price | $75.25 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 5.4M | 583.4K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $331,952,000.00 | $39,211,000.00 |
| Revenue This Year | $100.51 | $10.61 |
| Revenue Next Year | $60.41 | $8.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 147.15 | N/A |
| 52 Week Low | $37.81 | $45.84 |
| 52 Week High | $100.25 | $130.05 |
Technical Indicators
Market Signals| Indicator | MP | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 52.28 |
| Support Level | $44.43 | $108.87 |
| Resistance Level | $62.90 | $120.37 |
| Average True Range (ATR) | 3.13 | 5.07 |
| MACD | -0.74 | -0.99 |
| Stochastic Oscillator | 2.20 | 32.10 |
Price Performance
Historical ComparisonAbout MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.